公司資料
Phathom Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- PHAT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
9.28 USD (-3.13%)
收盤價
最後更新: 2026年8月17日
770M USD
市值
股價為何變動
As of Aug 17, 2026, PHAT closed down 3.13% at $9.28. No new same-company headline was identified in the current news window.
公司概覽
Gastrointestinal Medicines
Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker.
VOQUEZNA Franchise
VOQUEZNA is marketed in the United States for heartburn associated with non-erosive gastroesophageal reflux disease, healing and maintenance of erosive GERD, and as dual- or triple-drug packs for Helicobacter pylori infection. Its mechanism provides rapid and durable acid suppression distinct from proton-pump inhibitors.
Eosinophilic Esophagitis Development
The Phase 2 pHalcon-EoE-201 trial is evaluating VOQUEZNA in eosinophilic esophagitis. This program tests whether strong acid suppression can benefit a chronic inflammatory esophageal disease and extend the franchise into another specialist-treated indication.
未來催化劑
- Topline results from the Phase 2 pHalcon-EoE-201 trial expected in late fourth-quarter 2026 or early first-quarter 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。